Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DC/Myeloma Fusion Vaccine with Lenalidomide Maintenance in MM
NCT02728102Phase 2Completed
- Sponsor
- National Heart, Lung, and Blood Institute
- Start
- Jul 2016
- Primary completion
- Jun 2020
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of dendritic cell-myeloma fusion vaccine in multiple myeloma (MM), sponsored by National Heart, Lung, and Blood Institute. Started Jul 2016; status: completed.
02
Drugs
dendritic cell-myeloma fusion vaccine
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02728102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02728102.